Champions Oncology, Inc. (CSBR) vs Kalaris Therapeutics Inc (KLRS)
A side-by-side comparison of Champions Oncology, Inc. and Kalaris Therapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSBR
Champions Oncology, Inc.
$4.85HealthcareDelayed quote: Oct 6, 2026, 12:04 PM EDT
KLRS
Kalaris Therapeutics Inc
$2.90HealthcareDelayed quote: Oct 6, 2026, 12:02 PM EDT
Total return — CSBR vs KLRS
growth of $100 · dividends reinvested · last 10yCSBR +196.0% (+11.5%/yr)KLRS -99.1% (-37.3%/yr)CSBR compounded faster over this window
Log scale — wide-divergence pair
CSBR KLRS
CSBR vs KLRS: by the numbers
- •CSBR is the larger company ($67M vs $63M market cap).
- •Both run net losses; KLRS's is the smaller (0.00% vs -1.87% net margin).
Metrics side by side
Valuation
| Metric | CSBR | KLRS |
|---|---|---|
| Forward P/E | 48.50 | N/A |
| P/S ratio | 1.11 | N/A |
| P/B ratio | 17.31 | 1.10 |
| EV / EBITDA | 254.28 | N/A |
Profitability
| Metric | CSBR | KLRS |
|---|---|---|
| Gross margin | 49.30% | 0.00% |
| Operating margin | -1.72% | 0.00% |
| Net margin | -1.87% | 0.00% |
| ROE | -29.15% | -76.75% |
| ROIC | -6.75% | -52.40% |
Growth (annualized)
| Metric | CSBR | KLRS |
|---|---|---|
| Revenue CAGR (5Y) | 7.25% | N/A |
| Total return CAGR (5Y) | -13.07% | -81.13% |
Frequently asked
- How have CSBR and KLRS total returns compared?
- Over the past 5 years, CSBR delivered -13.07% and KLRS delivered -81.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.